Related Experiment Video

Updated: Jun 21, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

[Heart rate reduction: beneficial effects in heart failure and post-infarcted myocardium]

Alain Berdeaux1, Renaud Tissier, Nicolas Couvreur

  • 1Laboratoire de Pharmacologie, Faculté de Médecine de Créteil et Fédération de Cardiologie de l'Hôpital Henri Mondor, Créteil, France. alain.berdeaux@inserm.fr

Therapie
|August 12, 2009
PubMed

Insights

Reducing heart rate (HR) with beta-blockers or ivabradine benefits advanced heart failure patients. Further trials are needed to determine optimal therapeutic strategies for these conditions.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Heart rate (HR) is a key predictor of cardiovascular events in advanced heart failure.
  • Reducing HR with medications like beta-blockers and ivabradine improves outcomes in heart failure and post-infarction patients.

Purpose of the Study:

  • To review the effects of HR reduction on cardiovascular events and remodeling.
  • To compare the mechanisms of action of beta-blockers and ivabradine.
  • To explore optimal therapeutic strategies for advanced heart failure.

Main Methods:

  • Review of clinical trials on beta-blockers and ivabradine.
  • Analysis of HR reduction mechanisms and effects on fibrosis and remodeling.
  • Comparison of drug effects on post-systolic contraction.

Main Results:

  • HR reduction by beta-blockers and ivabradine leads to favorable effects in heart failure and post-infarction patients.
  • Benefits include reduced myocardial ischemia risk factors and decreased cardiac/perivascular fibrosis.
  • Mechanisms differ, particularly regarding effects on post-systolic contraction.

Conclusions:

  • Both beta-blockers and ivabradine demonstrate efficacy in reducing HR and improving outcomes.
  • Distinct mechanisms of action necessitate further research.
  • Clinical trials are required to ascertain whether to substitute or combine these drugs for optimal patient management.

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.